For: | Kim HS, Yim HJ, Jang MK, Park JW, Suh SJ, Seo YS, Kim JH, Kim BH, Park SJ, Lee SH, Kim SG, Kim YS, Lee JI, Lee JW, Kim IH, Kim TY, Kim JW, Jeong SH, Jung YK, Park H, Group SGHOBOARS. Management of entecavir-resistant chronic hepatitis B with adefovir-based combination therapies. World J Gastroenterol 2015; 21(38): 10874-10882 [PMID: 26478678 DOI: 10.3748/wjg.v21.i38.10874] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v21/i38/10874.htm |
Number | Citing Articles |
1 |
Bo Qin, Yechao Zhou, Guozhong Zhou, Xiuping Xu, Yanan Wang, Jinkun Chen. Substitutions of rtL228 and/or L229 are involved in the regulation of replication and HBsAg secretion in hepatitis B virus, and do not affect susceptibility to nucleos(t)ide analogs. Molecular Medicine Reports 2017; 16(6): 9678 doi: 10.3892/mmr.2017.7778
|
2 |
Hubert G. M. Niesters, Annelies Riezebos-Brilman, Coretta C. Van Leer-Buter. Manual of Molecular and Clinical Laboratory Immunology. 2016; : 620 doi: 10.1128/9781555818722.ch65
|
3 |
Marisa Doher, Natália Borges Cardin, Alexandre W.S. de Souza, Gianna Mastroianni Kirsztajn. Polyarteritis Nodosa and Membranous Glomerulonephritis. JCR: Journal of Clinical Rheumatology 2021; 27(2): e45 doi: 10.1097/RHU.0000000000000844
|
4 |
Kileen L. Shier. Manual of Molecular and Clinical Laboratory Immunology. 2024; : 600 doi: 10.1002/9781683674023.ch57
|
5 |
Forough Golsaz-Shirazi, Fazel Shokri. Hepatitis B Immunopathogenesis and Immunotherapy. Immunotherapy 2016; 8(4): 461 doi: 10.2217/imt.16.3
|
6 |
Lujie Liu, Yan Liu, Rongjuan Chen, Xiaodong Li, Dan Luo, Yangyang Zhao, Qi Li, Bixia Huang, Fu-Sheng Wang, Xinguang Liu, Dongping Xu. Prevalence of the entecavir-resistance-inducing mutation rtA186T in a large cohort of Chinese hepatitis B virus patients. Antiviral Research 2019; 164: 131 doi: 10.1016/j.antiviral.2019.02.012
|
7 |
Caifang Chang, Chenxu Guo, Xiaoxia Yuan, Jingjing Fan, Zhihong Ji, Chen Yong. Effect of entecavir plus peginterferon α-2a on hepatitis B virus-RNA, IL-21 expression level, immune function and prognosis in patients with hepatitis B. Materials Express 2023; 13(4): 618 doi: 10.1166/mex.2023.2382
|
8 |
Jin Shang, Juan Zhou, Huan Liu, Rili M. Ise, You Tu, Jinqiu Ran, Lang Bai, Hong Tang. Efficacy of different nucleoside analog rescue therapies for entecavir-resistant chronic hepatitis B patients. BMC Infectious Diseases 2021; 21(1) doi: 10.1186/s12879-021-06554-1
|
9 |
Si-Si Yang, Cheng-Wei Cai, Xue-Qing Ma, Jia Xu, Cheng-Bo Yu. Efficacy and cost-effectiveness of antiviral regimens for entecavir-resistant hepatitis B: A systematic review and network meta-analysis. Hepatobiliary & Pancreatic Diseases International 2020; 19(6): 507 doi: 10.1016/j.hbpd.2020.09.007
|
10 |
Wei Wang, Yi Shu, Han Bao, Wenliang Zhao, Weihua Wang, Qin Wang, Xiaoying Lei, Daxiang Cui, Zhen Yan. Genotypes and Hot Spot Mutations of Hepatitis B Virus in Northwest Chinese Population and Its Correlation with Diseases Progression. BioMed Research International 2019; 2019: 1 doi: 10.1155/2019/3890962
|
11 |
An Goto, Raul Rodriguez-Esteban, Sebastian H. Scharf, Garrett M. Morris. Understanding the genetics of viral drug resistance by integrating clinical data and mining of the scientific literature. Scientific Reports 2022; 12(1) doi: 10.1038/s41598-022-17746-3
|
12 |
Jun Chen, Shu-Shan Zhao, Xiao-xiao Liu, Ze-Bing Huang, Yan Huang. Comparison of the Efficacy of Tenofovir Versus Tenofovir plus Entecavir in the Treatment of Chronic Hepatitis B in Patients With Poor Efficacy of Entecavir: A Systematic Review and Meta-analysis. Clinical Therapeutics 2017; 39(9): 1870 doi: 10.1016/j.clinthera.2017.07.015
|
13 |
Young Eun Ahn, Sang Jun Suh, Tae Hyung Kim, Young Kul Jung, Hyung Joon Yim. Maintaining Antiviral Efficacy after Switching to Generic Entecavir 1 mg for Antiviral-resistant Chronic Hepatitis B. The Korean Journal of Gastroenterology 2021; 77(1): 22 doi: 10.4166/kjg.2020.0144
|